EUCTR2009-011020-65-BE进行中（未招募）1 期
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.
European Organisation for Research and Treatment of Cancer0 个研究点目标入组 105 人开始时间: 2011年4月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Advanced stage mycosis fungoides (stage IIB-IV), or Sézary Syndrome.
- •? Prior debulking therapy with either mono-chemotherapy, Poly-chemotherapy/combination chemo and radiotherapy or radiotherapy alone (e.g. Total Skin Electron Beam body radiation [TSEB]) (according to local institutional guidelines) resulting in complete or partial response as defined in this protocol's Evaluation criteria chapter. At the time of registration, patients provide consent for the collection of this pre/post debulking assessment information.
- •? For patients with Sézary syndrome, Sézary cell burden has to be decreased by at least 50 percent after debulking.
- •? Local low-dose/energy ionizing radiation therapy may be used as part of the debulking process in combination with chemotherapy.
- •? High dose steroids may be used as part of the debulking regimen as per local institution protocols, but must have been discontinued by the end of debulking and at the time of disease response assessment.
- •? Disease not appropriate for skin-directed therapy, per local institution standards.
- •? Disease not previously treated with intravenous anti-neoplastic agents (except for the debulking agents, used for that purpose immediately prior to this protocol).
- •? Age > 18 years.
- •? WHO performance status 0-2.
- •? Life expectance greater than 12 months.
- •? Patients with high risk for or history of a thromboembolic event must agree to receive prophylactic anti-coagulation therapy to keep the International normalized ratio (INR) in the range of 2-3.
- •? No second malignancies in the 3 years prior to study entry with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the skin.
- •? Female subjects of childbearing potential (as defined in the protocol) must agree to use an appropriate form of contraception, as defined in chapter 3 'Patient seclection criteria'.
- •? Male subjects must agree to use condoms throughout study drug therapy and follow guidelines, as described in chapter 3 'Patient seclection criteria'.
- •? Written informed consent must be given according to the International Conference on Harmonisation (ICH) Harmonized Tripartite Guideline on Good Clinical Practice (ICH/GCP), and national/local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •? Central nervous system involvement.
- •? Uncontrolled infectious disease, autoimmune disease, immunodeficiency, or history of either splenectomy or splenic irradiation.
- •? No pregnant or breast feeding subjects.
- •? No Lapp lactase deficiency or history of glucose-galactose malabsorption.
- •? Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
研究者
相似试验
进行中（未招募）
1 期
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 14.1Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864EUCTR2009-011020-65-DEEuropean Organisation for Research and Treatment of Cancer30
进行中（未招募）
1 期
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 14.1 Level: LLT Classification code 10028508 Term: Mycosis fungoides/Sezary syndrome System Organ Class: 100000004864EUCTR2009-011020-65-GBEuropean Organisation for Research and Treatment of Cancer30
撤回
3 期
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.Cutaneous lymphomaMycosis Fungoides1002532110040900NL-OMON38396European Organisation for Research in Treatment of Cancer (EORTC)10
进行中（未招募）
不适用
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 12.0Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeEUCTR2009-011020-65-NLEuropean Organisation for Research and Treatment of Cancer105
进行中（未招募）
1 期
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 12.0 Level: LLT Classification code 10028508 Term: Mycosis fungoides/Sezary syndromeEUCTR2009-011020-65-FREuropean Organisation for Research and Treatment of Cancer30